Elos Medtech AB (publ) has signed an amendment to an existing agreement with a global healthcare customer active in the fields of diabetes and other chronic diseases, to provide an additional CNY 90 million in annual production output by the end of 2025. The additional volume will be made by the production site in Tianjin for the Chinese market. Elos Medtech has committed to invest approximately CNY 50 million in production equipment during a two-year period to increase the output capacity to meet future demand for the Chinese market.

Elos Medtech Tianjin generates revenue of approximately CNY 70 million per year serving both the life science and dental industries from its 7,000 square meter production facility. The local business focus enables Elos Medtech to service both local and international customers, directly at the local Chinese market. At Elos Medtech it is called “Global/Local”.

In an ever-changing business environment, this concept is becoming increasingly important to facilitate and secure global supply for Elos Medtech's global customers in the Chinese market.